# Audit Report: TFDA Risk Management Plan (XELJANZ)

## ğŸ“‚ Data Provenance & Integrity (Taiwan)
To ensure the auditability of the pharmaceutical data, the source document from Taiwan TFDA is anchored below.

- [cite_start]**Source Document:** Risk Evaluation and Mitigation Strategy (REMS) Public Version [cite: 34]
- [cite_start]**Drug Name:** XELJANZ (tofacitinib) [cite: 31]
- [cite_start]**Manufacturer:** Pfizer (è¼ç‘å¤§è—¥å» ) [cite: 32]
- **SHA-256 Hash:** `707C3AC511499AFC27829C6F3264C9277908E20A3C413FD234D2B1469D4AE770`
- [cite_start]**Document Version:** April 2015 [cite: 281]

---

## ğŸ” Regulatory Timeline: Taiwan TFDA
- [cite_start]**Official Approval Date:** December 12, 2013 [cite: 53]
- **Approval Number:** è¡›éƒ¨è—¥è¼¸å­—ç¬¬026219è™Ÿ
- [cite_start]**Indication:** Treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) [cite: 60]

---

## âš ï¸ Safety Monitoring & Risks (REMS)
The TFDA mandates a strict Risk Evaluation and Mitigation Strategy (REMS) for this product due to the following serious risks:
- [cite_start]**Serious Infections:** Increased risk of tuberculosis (TB), invasive fungal infections, and other bacterial or viral infections[cite: 68, 69].
- [cite_start]**Malignancies:** Reports of lymphoma and other malignancies during clinical studies[cite: 81].
- [cite_start]**Laboratory Abnormalities:** Required monitoring for Lymphocytes, Neutrophils, Hemoglobin, and Lipids[cite: 87].

---

## ğŸ“Š Cross-Border Benchmarking
- **US FDA Approval:** November 6, 2012
- **Taiwan TFDA Approval:** December 12, 2013
- **Administrative Lag:** **13 months**
- **Audit Observation:** The 13-month delay reflects the time required for establishing localized REMS and safety monitoring protocols in Taiwan.

---
*This document is part of the **OncoAudit (v2.0.0)** research series.*
